RE: BSE Postmortem Test AnnouncementWhile this IDEXX news is noteworthy, I dont see it as being a negative for Prometic at all. Prometic's largest imminent revenue stream related to BSE will come from its fundamental ability to REMOVE BSE prions from Blood using the PRDT filter. There's a huge market for the filter itself with all of the varied applications.
Its noteworthy that this news relates specifically to post mortem testing. If you consider that Prometic has the ability to remove BSE prions from BLOOD using the PRDT filter. Its not a stretch to think that PLI's technology could be used to remove Prions from the blood of a live animal. The key would then be the ability to detect the prions presence and to come up with a quick and reliable field test result. I think that is the holy grail.
It would be nice if the company could give us some specific direction in this regard given the magnitude of the opportunity specifically relating to Live Testing.